skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Novel interferon-{lambda}s induce antiproliferative effects in neuroendocrine tumor cells

Journal Article · · Biochemical and Biophysical Research Communications
 [1];  [1];  [1];  [1];  [1];  [1];  [2];  [1]
  1. Department of Internal Medicine II, University-Hospital Munich-Grosshadern, University of Munich, Munich (Germany)
  2. Physiology Weihenstephan, TU Munich, Freising (Germany)

Interferon-{alpha} (IFN-{alpha}) is used for biotherapy of neuroendocrine carcinomas. The interferon-{lambda}s (IL-28A/B and IL-29) are a novel group of interferons. In this study, we investigated the effects of the IFN-{lambda}s IL-28A and IL-29 on human neuroendocrine BON1 tumor cells. Similar to IFN-{alpha}, incubation of BON1 cells with IL-28A (10 ng/ml) and IL-29 (10 ng/ml) induced phosphorylation of STAT1, STAT2, and STAT3, significantly decreased cell numbers in a proliferation assay, and induced apoptosis as demonstrated by poly(ADP-ribose) polymerase (PARP)-cleavage, caspase-3-cleavage, and DNA-fragmentation. Stable overexpression of suppressor of cytokine signaling proteins (SOCS1 and SOCS3) completely abolished the aforementioned effects indicating that SOCS proteins act as negative regulators of IFN-{lambda} signaling in BON1 cells. In conclusion, the novel IFN-{lambda}s IL-28A and IL-29 potently induce STAT signaling and antiproliferative effects in neuroendocrine BON1 tumor cells. Thus, IFN-{lambda}s may hint a promising new approach in the antiproliferative therapy of neuroendocrine tumors.

OSTI ID:
20799004
Journal Information:
Biochemical and Biophysical Research Communications, Vol. 344, Issue 4; Other Information: DOI: 10.1016/j.bbrc.2006.04.043; PII: S0006-291X(06)00879-5; Copyright (c) 2006 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved; Country of input: International Atomic Energy Agency (IAEA); ISSN 0006-291X
Country of Publication:
United States
Language:
English